Home/Filings/4/0001179110-11-015979
4//SEC Filing

GETLIN LAWRENCE W 4

Accession 0001179110-11-015979

CIK 0001222244other

Filed

Dec 1, 7:00 PM ET

Accepted

Dec 2, 4:59 PM ET

Size

13.4 KB

Accession

0001179110-11-015979

Insider Transaction Report

Form 4
Period: 2011-12-02
Transactions
  • Award

    Common stock, $0.00001 par value

    2011-12-01$1.10/sh+23,182$25,50027,728 total
  • Award

    Convertible Note

    2011-12-01$1.00/sh
    Exercise: $1.10Exp: 2012-02-28Common stock, $0.00001 par value
  • Award

    Common stock, $0.00001 par value

    2011-12-01$1.10/sh+4,546$5,0014,546 total
Holdings
  • Stock Options

    Exercise: $0.92Exp: 2018-02-27Common Stock, $0.00001 par value (2,265 underlying)
    2,265
  • Convertible notes

    Exercise: $1.30Exp: 2013-09-15Common Stock, $0.00001 par value (19,231 underlying)
  • Stock Options

    Exercise: $0.87Exp: 2018-08-09Common stock, $0.00001 par value (28,736 underlying)
    28,736
Footnotes (6)
  • [F1]Options vest as to 189 shares per month begining July 27, 2011, and as to 185 shares on June 27, 2012.
  • [F2]Currently exercisable.
  • [F3]Annual option award pursuant to the Issuer's compensation policy for Directors upon their re-election to the Board of Directors at its annual shareholders' meeting. The seven-year options vest ratably over 12 months.
  • [F4]On December 1, 2011, the reporting person and the Company executed a convertible promissory note in the principal amount of $5,200 with a maturity date of February 28, 2012. The principal amount and interest accruing at a rate of 10% per year are convertible into common shares at $1.10 per share at any time through the maturity date. The number of shares to be issued upon conversion will be fixed on the conversion date and reported on a Form 4 within 2 business days after conversion. The issuer's Board of Directors specifically approved the transaction as exempt from the requirements of Section 16b as provided by Rules 16b-3(d).
  • [F5]Shares issued in lieu of cash for directors' fees as approved by the Board of Directors which are exempt under section 16b-3(d).
  • [F6]On December 1, 2011, the issuer issued 23,182 shares to the reporting person in lieu of cash for consulting fees due to the reporting person. The issuer's Board of Directors specifically approved the transaction as exempt from the requirements of Section 16b as provided by Rules 16b-3(d).

Issuer

ProUroCare Medical Inc.

CIK 0001222244

Entity typeother

Related Parties

1
  • filerCIK 0001230359

Filing Metadata

Form type
4
Filed
Dec 1, 7:00 PM ET
Accepted
Dec 2, 4:59 PM ET
Size
13.4 KB